Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04527471 · ClinicalTrials.gov registry record · Phase 2
Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19
A Phase 2 study, sponsored by Verona Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT04527471 is a Phase 2 study that has completed, run by Verona Pharma. The registered enrollment target is 45 participants.
The verdict
NCT04527471, a Phase 2 study, has completed, sponsored by Verona Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
This pilot study is being performed to assess the efficacy and safety of inhaled ensifentrine delivered via pMDI compared with a matching placebo in conjunction with standard of care treatments on recovery in patients hospitalized due to COVID-19 infection.
Interventions
- DRUG Ensifentrine Dose 1
- DRUG Placebo pMDI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2020-09-04 |
| Est. Completion | 2021-05-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04527471
The ClinicalTrials.gov registry entry for NCT04527471 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Verona Pharma, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ensifentrine Dose 1 is the first listed.
NCT04527471 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04527471 about?
NCT04527471 is a clinical study titled "Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19". This pilot study is being performed to assess the efficacy and safety of inhaled ensifentrine delivered via pMDI compared with a matching placebo in conjunction with standard of care treatments on recovery in patients hospitalized due to COVID-19 infection.
What is the current status of trial NCT04527471?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2020-09-04. Estimated completion is 2021-05-01.
What interventions are being tested in trial NCT04527471?
The interventions under investigation include: Ensifentrine Dose 1 (DRUG), Placebo pMDI (DRUG).
Who is sponsoring clinical trial NCT04527471?
This trial is sponsored by Verona Pharma, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.